메뉴 건너뛰기




Volumn 54, Issue 1, 2012, Pages 47-59

Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico

Author keywords

Antibodies; Cost effectiveness; Mexico; Monoclonal; QALY; Respiratory syncytial virus

Indexed keywords

ANTIVIRUS AGENT; MONOCLONAL ANTIBODY; PALIVIZUMAB;

EID: 84858687592     PISSN: 00363634     EISSN: 16067916     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (15)

References (48)
  • 1
    • 0032988719 scopus 로고    scopus 로고
    • Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion
    • Meissner HC, Welliver RC, Chartrand SA, Law BJ, Weisman LE, Dorkin HL, et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J 1999;18(3):223-231.
    • (1999) Pediatr Infect Dis J , vol.18 , Issue.3 , pp. 223-231
    • Meissner, H.C.1    Welliver, R.C.2    Chartrand, S.A.3    Law, B.J.4    Weisman, L.E.5    Dorkin, H.L.6
  • 2
    • 0027384670 scopus 로고
    • Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group
    • Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodríguez WJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993;329(21): 1524-1530.
    • (1993) N Engl J Med , vol.329 , Issue.21 , pp. 1524-1530
    • Groothuis, J.R.1    Simoes, E.A.2    Levin, M.J.3    Hall, C.B.4    Long, C.E.5    Rodríguez, W.J.6
  • 3
    • 0034821962 scopus 로고    scopus 로고
    • Tasas de hospitalización por infección por virus respiratorio sincitial en prematuros nacidos en dos estaciones consecutivas
    • and the IRIS Study Group
    • Carbonell-Estrany X, Quero J, and the IRIS Study Group. Tasas de hospitalización por infección por virus respiratorio sincitial en prematuros nacidos en dos estaciones consecutivas. Pediatr Infect Dis J 2001;20(9):874-879.
    • (2001) Pediatr Infect Dis J , vol.20 , Issue.9 , pp. 874-879
    • Carbonell-Estrany, X.1    Quero, J.2
  • 4
    • 0036550430 scopus 로고    scopus 로고
    • The association between respiratory syncytial virus infection and reactive airway disease
    • Piedimonte G. The association between respiratory syncytial virus infection and reactive airway disease. Respir Med 2002; 96 Suppl B:S25-S29.
    • (2002) Respir Med , vol.96 , Issue.SUPPL. B
    • Piedimonte, G.1
  • 6
    • 77958471150 scopus 로고    scopus 로고
    • Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life
    • doi: 10.1136/thx.2009.121582
    • Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbersgsson F, Bjarnason R, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010; 65(12):1045-1052. doi:10.1136/thx.2009.121582.
    • (2010) Thorax , vol.65 , Issue.12 , pp. 1045-1052
    • Sigurs, N.1    Aljassim, F.2    Kjellman, B.3    Robinson, P.D.4    Sigurbersgsson, F.5    Bjarnason, R.6
  • 7
    • 27544514554 scopus 로고    scopus 로고
    • Palivizumab in the prophylaxis of respiratory syncytial virus infection
    • Cardenas S, Auais A, Piedimonte G. Palivizumab in the prophylaxis of respiratory syncytial virus infection. Expert Rev Anti Infect Ther 2005;3(5):719-726.
    • (2005) Expert Rev Anti Infect Ther , vol.3 , Issue.5 , pp. 719-726
    • Cardenas, S.1    Auais, A.2    Piedimonte, G.3
  • 9
    • 46749106012 scopus 로고    scopus 로고
    • Respiratory syncytial virus infection and recurrent wheezing: what next?
    • Puddu M, Fanos V. Respiratory syncytial virus infection and recurrent wheezing: what next? J Chemother 2007;19 Suppl 2:8-11.
    • (2007) J Chemother , vol.19 , Issue.SUPPL. 2 , pp. 8-11
    • Puddu, M.1    Fanos, V.2
  • 10
    • 2442522194 scopus 로고    scopus 로고
    • Impact of whezzing after respiratory syncytial virus infection on healthrelated quality of life
    • Bont L, Steijn M, Van Aalderen WM, Kimpen JL. Impact of whezzing after respiratory syncytial virus infection on healthrelated quality of life. Pediatr Infect Dis J 2004;23(5):414-417.
    • (2004) Pediatr Infect Dis J , vol.23 , Issue.5 , pp. 414-417
    • Bont, L.1    Steijn, M.2    Van Aalderen, W.M.3    Kimpen, J.L.4
  • 11
    • 3042760382 scopus 로고    scopus 로고
    • Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection
    • Greenough A, Alexander J, Burgess S, Bytham J, Chetcuti PA, Hagan J, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 2004;89(7): 673-678.
    • (2004) Arch Dis Child , vol.89 , Issue.7 , pp. 673-678
    • Greenough, A.1    Alexander, J.2    Burgess, S.3    Bytham, J.4    Chetcuti, P.A.5    Hagan, J.6
  • 12
    • 84858688295 scopus 로고    scopus 로고
    • World Health Organization (WHO). [Update September 2009]. [Accessed 2009 November] Available at
    • World Health Organization (WHO). Respiratory syncytial virus and parainfluenza viruses. [Update September 2009]. [Accessed 2009 November] Available at: http://www.who.int/vaccine_research/diseases/ ari/en/index2.html
    • Respiratory syncytial virus and parainfluenza, viruses.
  • 13
    • 0032696770 scopus 로고    scopus 로고
    • Bronchiolitis-associated hospitalizations among US children, 1980-1996
    • Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999;282(15):1440-1446.
    • (1999) JAMA , vol.282 , Issue.15 , pp. 1440-1446
    • Shay, D.K.1    Holman, R.C.2    Newman, R.D.3    Liu, L.L.4    Stout, J.W.5    Anderson, L.J.6
  • 14
    • 0035927982 scopus 로고    scopus 로고
    • Respiratory syncytial virus and parainfluenza virus
    • Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001;344(25):1917-1928.
    • (2001) N Engl J Med , vol.344 , Issue.25 , pp. 1917-1928
    • Hall, C.B.1
  • 15
    • 0842327826 scopus 로고    scopus 로고
    • National disease burden of respiratory viruses detected in children by polymerase chain reaction
    • Henrickson KJ, Hoover S, Kehl KS, Hua W. National disease burden of respiratory viruses detected in children by polymerase chain reaction. Pediatr Infect Dis J 2004;23(1 Suppl):S11-S118.
    • (2004) Pediatr Infect Dis J , vol.23 , Issue.1 SUPPL.
    • Henrickson, K.J.1    Hoover, S.2    Kehl, K.S.3    Hua, W.4
  • 16
    • 0026541731 scopus 로고
    • The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries
    • Garenne M, Ronsmans C, Campbell H. The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries. World Health Stat Q 1992; 45(2-3):180-191.
    • (1992) World Health Stat Q , vol.45 , Issue.2-3 , pp. 180-191
    • Garenne, M.1    Ronsmans, C.2    Campbell, H.3
  • 17
    • 33749473106 scopus 로고    scopus 로고
    • Costeffectiveness Analysis of Palivizumab in Premature Infants Without Chronic Lung Disease
    • ElHassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW. Costeffectiveness Analysis of Palivizumab in Premature Infants Without Chronic Lung Disease. Arch Pediatr Adolesc Med 2006;160(10):1070-1076.
    • (2006) Arch Pediatr Adolesc Med , vol.160 , Issue.10 , pp. 1070-1076
    • ElHassan, N.O.1    Sorbero, M.E.2    Hall, C.B.3    Stevens, T.P.4    Dick, A.W.5
  • 18
    • 67650090676 scopus 로고    scopus 로고
    • Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
    • Chirico G, Ravasio R, Sbarigia U. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Italian J Pediatr 2009;35(1):4.
    • (2009) Italian J Pediatr , vol.35 , Issue.1 , pp. 4
    • Chirico, G.1    Ravasio, R.2    Sbarigia, U.3
  • 20
    • 76649093908 scopus 로고    scopus 로고
    • Cost effectiveness of palivizumab in Spain: an analysis using observational data
    • Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ 2010;11(1):105-115.
    • (2010) Eur J Health Econ , vol.11 , Issue.1 , pp. 105-115
    • Nuijten, M.J.1    Wittenberg, W.2
  • 21
    • 84858634376 scopus 로고    scopus 로고
    • Secretaría de Gobernación. Felipe Calderón Hinojosa. Pag 270. [Accessed 2009 November 6]. Available at
    • Secretaría de Gobernación. Anexo Estadístico Tercer Informe de Gobierno. Felipe Calderón Hinojosa. 2009. Pag 270. [Accessed 2009 November 6]. Available at: http://www.informe.gob.mx/anexo_ estadistico/pdf/2_3.pdf.
    • (2009) Anexo Estadístico Tercer Informe de Gobierno
  • 22
    • 84858634971 scopus 로고    scopus 로고
    • Instituto Nacional de Estadística y Geografía. XII Censo General de Población y Vivienda 2000. México: INEGI
    • Instituto Nacional de Estadística y Geografía. XII Censo General de Población y Vivienda 2000. México: INEGI, 2000.
    • (2000)
  • 23
    • 84858659718 scopus 로고    scopus 로고
    • Instituto Nacional de Estadística y Geografía. II Conteo de Población y Vivienda 2005. México: INEGI
    • Instituto Nacional de Estadística y Geografía. II Conteo de Población y Vivienda 2005. México: INEGI, 2006.
    • (2006)
  • 24
    • 84858634974 scopus 로고    scopus 로고
    • Instituto Mexicano del Seguro Social (IMSS). Asistencia Infantil. Peso y Edad Gestacional Enero-Junio
    • Instituto Mexicano del Seguro Social (IMSS). Estadísticas Médicas DATA MART. Asistencia Infantil. Peso y Edad Gestacional Enero-Junio 2009. [Accessed 2009 September 15]. Available at: http://www.imss.gob. mx/dpm/dis/Tabla.aspx?ID=SCRS04_0020_09&OPC=opc04&SRV=M00-1
    • (2009) Estadísticas Médicas, DATA., MART.
  • 25
    • 84858696535 scopus 로고    scopus 로고
    • Consejo Nacional de Población (CONAPO). [Accessed 2009 November]. Available at
    • Consejo Nacional de Población (CONAPO). Indicadores demográficos básicos 1990-2030.[Accessed 2009 November]. Available at: http://www.conapo.gob.mx/index.php?option=com_content&view=arti cle&id=125&Itemid=193
    • Indicadores demográficos básicos, 1990-2030.
  • 26
    • 84858634376 scopus 로고    scopus 로고
    • Secretaría de Gobernación. Felipe Calderón Hinojosa. Pag 59. [Accessed 2009 October 15] Available at
    • Secretaría de Gobernación. Anexo Estadístico Tercer informe de Gobierno. Felipe Calderón Hinojosa. 2009. Pag 59. [Accessed 2009 October 15] Available at: http://www.informe.gob.mx/anexo_estadistico/ pdf/1_4.pdf.
    • (2009) Anexo Estadístico Tercer informe de Gobierno.
  • 27
    • 2642543386 scopus 로고    scopus 로고
    • A new growth chart for preterm babies: Babson and Benda's chart updated with recent data and a new format
    • Fenton TR. A new growth chart for preterm babies: Babson and Benda's chart updated with recent data and a new format. BMC Pedriatr 2003;16; 3:13
    • (2003) BMC Pedriatr , vol.16 , Issue.3 , pp. 13
    • Fenton, T.R.1
  • 28
    • 84858659719 scopus 로고    scopus 로고
    • National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion. USA. [Accessed 2009 October]: Available at
    • National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000). USA. [Accessed 2009 October]: Available at: http://www.cdc.gov/ growthcharts
    • (2000)
  • 29
    • 0024361503 scopus 로고
    • The Tucson Children's Respiratory Study. II. Lower respiratory tract illness in the first year of life
    • Wright AL, Taussig LM, Ray CG, Harrison HR, Holberg CJ. The Tucson Children's Respiratory Study. II. Lower respiratory tract illness in the first year of life. Am J Epidemiol 1989; 129(6):1232-1246.
    • (1989) Am J Epidemiol , vol.129 , Issue.6 , pp. 1232-1246
    • Wright, A.L.1    Taussig, L.M.2    Ray, C.G.3    Harrison, H.R.4    Holberg, C.J.5
  • 30
    • 0031990602 scopus 로고    scopus 로고
    • Respiratory syncytial virus
    • Darville T, Yamauchi T. Respiratory syncytial virus. Pediatr Rev 1998; 19(2):55-61
    • (1998) Pediatr Rev , vol.19 , Issue.2 , pp. 55-61
    • Darville, T.1    Yamauchi, T.2
  • 31
    • 4544336983 scopus 로고    scopus 로고
    • Viral infections of the lower respiratory tract
    • China: Taussig-Landau
    • Dubois B, Ray G. Viral infections of the lower respiratory tract. Pediatric Respiratory Medicine. China: Taussig-Landau, 1999; 573-579.
    • (1999) Pediatric Respiratory Medicine , pp. 573-579
    • Dubois, B.1    Ray, G.2
  • 32
    • 0141682395 scopus 로고    scopus 로고
    • Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants
    • and IRIS Study Group
    • Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, and IRIS Study Group. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 2003;22(9):823-827.
    • (2003) Pediatr Infect Dis J , vol.22 , Issue.9 , pp. 823-827
    • Pedraz, C.1    Carbonell-Estrany, X.2    Figueras-Aloy, J.3    Quero, J.4
  • 33
    • 0242298724 scopus 로고    scopus 로고
    • Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
    • Cardiac Synagis Study Group
    • Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al. Cardiac Synagis Study Group: Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143(4):532-540.
    • (2003) J Pediatr , vol.143 , Issue.4 , pp. 532-540
    • Feltes, T.F.1    Cabalka, A.K.2    Meissner, H.C.3    Piazza, F.M.4    Carlin, D.A.5    Top Jr., F.H.6
  • 34
    • 0031683919 scopus 로고    scopus 로고
    • Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
    • The Impact-RSV Study Group
    • The Impact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3):531-537.
    • (1998) Pediatrics , vol.102 , Issue.3 , pp. 531-537
  • 35
    • 6844242330 scopus 로고    scopus 로고
    • Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group
    • Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sánchez PJ, Steichen J, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 1998;17(2):110-115.
    • (1998) Pediatr Infect Dis J , vol.17 , Issue.2 , pp. 110-115
    • Subramanian, K.N.1    Weisman, L.E.2    Rhodes, T.3    Ariagno, R.4    Sánchez, P.J.5    Steichen, J.6
  • 36
    • 80455127363 scopus 로고    scopus 로고
    • Mortality and Morbidity Among High-Risk Preterm Infants Receiving Palivizumab Prophylaxis: A Systematic Review and Meta-Analysis
    • Checchia PA, Nalysnyk L, Fernandes A, Mahadevia P, Xu Y, Fahrbach K, et al. Mortality and Morbidity Among High-Risk Preterm Infants Receiving Palivizumab Prophylaxis: A Systematic Review and Meta-Analysis. Pediatric Crit Care Med. 2011;12(5):580-588.
    • (2011) Pediatric Crit Care Med , vol.12 , Issue.5 , pp. 580-588
    • Checchia, P.A.1    Nalysnyk, L.2    Fernandes, A.3    Mahadevia, P.4    Xu, Y.5    Fahrbach, K.6
  • 37
    • 33846796106 scopus 로고    scopus 로고
    • Costo-efficacia di palivizumab versus non profilassi nella prevenzione delle infezioni da VRS nei bambini pretermine, a diversa età gestazionale
    • Ravasio R, Lucioni C, Chirico G. Costo-efficacia di palivizumab versus non profilassi nella prevenzione delle infezioni da VRS nei bambini pretermine, a diversa età gestazionale. PharmacoEconomics - Italian Research Articles 2006; 8(2):105-117.
    • (2006) PharmacoEconomics - Italian Research Articles , vol.8 , Issue.2 , pp. 105-117
    • Ravasio, R.1    Lucioni, C.2    Chirico, G.3
  • 38
    • 84858634973 scopus 로고    scopus 로고
    • Instituto Mexicano del Seguro Social. Secretaria General de Aviso: Costos unitarios de la atención médica. Diario Oficial de la Federación. Martes 9 de marzo de. Primera Sección
    • Instituto Mexicano del Seguro Social. Secretaria General de Aviso: Costos unitarios de la atención médica. Diario Oficial de la Federación. Martes 9 de marzo de 2004. Primera Sección.
    • (2004)
  • 39
    • 84858634972 scopus 로고    scopus 로고
    • Instituto Mexicano del Seguro Social (IMSS). Portal de Transparencia. IMSS va a comprar, IMSS compró. Periodo Enero-Diciembre 2008 [Accessed November]. Available at
    • Instituto Mexicano del Seguro Social (IMSS). Portal de Transparencia. IMSS va a comprar, IMSS compró. Periodo Enero-Diciembre 2008: [Accessed 2009 November]. Available at: http://transparencia.imss.gob. mx/trnsp/ncompro.aspx?c=1
    • (2009)
  • 40
    • 84858634975 scopus 로고    scopus 로고
    • Banco de México. Inflación. [Accessed November 19]. Available at
    • Banco de México. Inflación. [Accessed 2009 November 19]. Available at: http://www.banxico.org.mx/portal-inflacion/index.html
    • (2009)
  • 41
    • 0036076496 scopus 로고    scopus 로고
    • Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease
    • Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002;22(4): 290-308.
    • (2002) Med Decis Making , vol.22 , Issue.4 , pp. 290-308
    • Briggs, A.H.1    Goeree, R.2    Blackhouse, G.3    O'Brien, B.J.4
  • 42
    • 16644380953 scopus 로고    scopus 로고
    • Direct Cost Analyses of Palivizumab Treatment in a Cohort of At-Risk Children: Evidence From the North Carolina Medicaid Program
    • Wegner S, Jacobson-Vann J, Liu G, Byrns P, Cypra C, Campbell W, et al. Direct Cost Analyses of Palivizumab Treatment in a Cohort of At-Risk Children: Evidence From the North Carolina Medicaid Program. Pediatrics 2004;114(6):1612-1619.
    • (2004) Pediatrics , vol.114 , Issue.6 , pp. 1612-1619
    • Wegner, S.1    Jacobson-Vann, J.2    Liu, G.3    Byrns, P.4    Cypra, C.5    Campbell, W.6
  • 43
    • 7444222237 scopus 로고    scopus 로고
    • Costo directo de la atención por crisis aguda de asma en el servicio de urgencias pediátricas
    • Martínez ZI, Bahena ME, Jurado LS, Hosking JE. Costo directo de la atención por crisis aguda de asma en el servicio de urgencias pediátricas. Rev Alergia Mex 2004; 51(4):134-138.
    • (2004) Rev Alergia Mex , vol.51 , Issue.4 , pp. 134-138
    • Martínez, Z.I.1    Bahena, M.E.2    Jurado, L.S.3    Hosking, J.E.4
  • 44
    • 84858646837 scopus 로고    scopus 로고
    • Banco de México. [Accessed November 19]. Available at
    • Banco de México. Mercado cambiario. [Accessed 2009 November 19]. Available at: http://www.banxico.org.mx/portal-mercado-cambiario/ index.html
    • (2009) Mercado cambiario
  • 45
    • 0038560087 scopus 로고    scopus 로고
    • World Health Organization. Health Systems: Improving Performance. Geneva Switzerland. [Accessed October]. Available at
    • World Health Organization. World Health Report 2000. Health Systems: Improving Performance. Geneva Switzerland. [Accessed 2009 October]. Available at: http://www.who.int/whr/2000/en/whr00_en.pdf
    • (2009) World Health Report 2000
  • 46
    • 11244261433 scopus 로고    scopus 로고
    • Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds
    • Jonsson B. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 2004; 22(suppl 4):5-10.
    • (2004) Pharmacoeconomics , vol.22 , Issue.SUPPL. 4 , pp. 5-10
    • Jonsson, B.1
  • 47
    • 84858680967 scopus 로고    scopus 로고
    • Instituto Nacional de Estadística y Geografía (INEGI). [Accessed November]. Available at
    • Instituto Nacional de Estadística y Geografía (INEGI). Sistema de Cuentas Nacionales. [Accessed 2009 November]. Available at: http:// dgcnesyp.inegi.org.mx/cgi-win/bdiecoy.exe/572?s=est&c=12546
    • (2009) Sistema de Cuentas Nacionales
  • 48
    • 84858633527 scopus 로고    scopus 로고
    • Consejo Nacional de Población (CONAPO). [Accessed October] Available at
    • Consejo Nacional de Población (CONAPO). Indicadores demográficos básicos 1990-2030. [Accessed 2009 October] Available at: http://www.conapo.gob.mx/index.php?option=com_content&view=article &id=125&Itemid=193.
    • (2009) Indicadores demográficos básicos 1990-2030


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.